Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study

SIMPLE SUMMARY: Despite the emergence of new therapies during the last decade, metastatic castration-resistant prostate cancer (mCRPC) remains fatal. Recent work showed that the timing of treatment initiation seems critical for patient outcomes. Thus, it is key to identify factors that can help in d...

Descripción completa

Detalles Bibliográficos
Autores principales: Delanoy, Nicolas, Robbrecht, Debbie, Eisenberger, Mario, Sartor, Oliver, de Wit, Ronald, Mercier, Florence, Geffriaud-Ricouard, Christine, de Bono, Johann, Oudard, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002173/
https://www.ncbi.nlm.nih.gov/pubmed/33805793
http://dx.doi.org/10.3390/cancers13061284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002173/
https://www.ncbi.nlm.nih.gov/pubmed/33805793
http://dx.doi.org/10.3390/cancers13061284

Ejemplares similares